# Study to Evaluate the Effect on Parameters of Systemic Inflammation and Disease Outcomes and Safety of RPH-104 in Subjects With Acute ST-elevation Myocardial Infarction

Study · id `cardio:ct-nct04463251` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT04463251](<https://clinicaltrials.gov/study/NCT04463251>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT04463251

Browse, organ or system: Heart  
Browse, condition area: Coronary and vascular disease; Acute care and long-term living  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 102 participants.

## Technical summary

Registry record NCT04463251. Randomized; double masking; primary purpose treatment. Start 2020-12-07 (actual); primary completion 2021-11-03 (actual). Results posted on 2024-01-24.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 102 participants (enrolled count; ClinicalTrials.gov record NCT04463251, source copy `cardio:ctgov-nct04463251-2024-06-24`, retrieved 2026-10-26)
- Started: 2020-12-07 (actual) (ClinicalTrials.gov record NCT04463251, source copy `cardio:ctgov-nct04463251-2024-06-24`, retrieved 2026-10-26)
- Primary completion: 2021-11-03 (actual) (ClinicalTrials.gov record NCT04463251, source copy `cardio:ctgov-nct04463251-2024-06-24`, retrieved 2026-10-26)
- Completion: 2022-10-10 (actual) (ClinicalTrials.gov record NCT04463251, source copy `cardio:ctgov-nct04463251-2024-06-24`, retrieved 2026-10-26)
- Results first posted: 2024-01-24 (ClinicalTrials.gov record NCT04463251, source copy `cardio:ctgov-nct04463251-2024-06-24`, retrieved 2026-10-26)
- Countries: United States; Russia (ClinicalTrials.gov record NCT04463251, source copy `cardio:ctgov-nct04463251-2024-06-24`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct04463251-2024-06-24`, retrieved 2026-10-26)

## The registry's words

- Brief title: Study to Evaluate the Effect on Parameters of Systemic Inflammation and Disease Outcomes and Safety of RPH-104 in Subjects With Acute ST-elevation Myocardial Infarction
- Condition: Acute ST Segment Elevation Myocardial Infarction
- Intervention (Biological): RPH-104 80 mg
- Intervention (Drug): Placebo
- Lead sponsor: R-Pharm Overseas, Inc.
- Lead sponsor class: INDUSTRY
- Collaborator: Cromos Pharma LLC
- Collaborator class: INDUSTRY
- Collaborator: Data Management 365
- Collaborator class: INDUSTRY
- Collaborator: Keystat, LLC
- Collaborator class: INDUSTRY
- Collaborator: R-Pharm
- Collaborator class: INDUSTRY
- Collaborator: K-Research, LLC
- Collaborator class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Heart attack (myocardial infarction) (`cardio:myocardial-infarction`)
- Registry condition terms include this condition: ST-elevation heart attack (STEMI) (`cardio:stemi`)

## Provenance

Content hash: 3c9d6be0566030ae740513f9c1a3f2e19d8838a73c8556c7d0793b451f6a8f8a
Last substantive edit: 2026-10-31
Evidence last checked: Not recorded
